Clinical trials: Active Acne
Acne Vulgaris
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris
- Trial name
- NCT00776919
- Testing
- clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel
- Where
- 24 sites in United States, Belize and 1 more
- Volunteers
- 1,315 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.
- Trial name
- NCT03433378
- Testing
- Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.
- Trial name
- NCT03427554
- Testing
- Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
- Where
- United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel…
- Trial name
- NCT03522441
- Testing
- Clindamycin 1% Gel
- Where
- 12 sites in United States, Belize
- Volunteers
- 1,125 people
- Sponsor
- Akorn, Inc.
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams…
- Trial name
- NCT02160678
- Testing
- Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%
- Where
- United States
- Volunteers
- 1,741 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Acne Vulgaris
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety.
- Trial name
- NCT02578043
- Testing
- Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%, Onexton™ Gel
- Volunteers
- 844 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of…
- Trial name
- NCT06673641
- Testing
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Acne Vulgaris
Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
- Trial name
- NCT01138514
- Testing
- Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo), Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
- Volunteers
- 1,555 people
- Sponsor
- Padagis LLC
Acne Vulgaris
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel…
- Trial name
- NCT01769235
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Acanya® Gel, 1.2%/2.5%, Vehicle of test product
- Volunteers
- 1,215 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the therapeutic equivalence and safety of Tazarotene Cream 0.1% and Tazorac® (tazarotene cream 0.1%).
- Trial name
- NCT02411955
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Volunteers
- 1,077 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
- Trial name
- NCT02411942
- Testing
- Adapalene Gel 0.3%, Differin®
- Volunteers
- 753 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Bioequivalence with Clinical Endpoints.
- Trial name
- NCT02709902
- Testing
- Adapalene/BP gel, 0.3%/2.5%, EPIDUO® FORTE
- Volunteers
- 460 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of…
- Trial name
- NCT02661958
- Testing
- S6G5T-3, S6G5T-1, S6G5T-5
- Where
- 34 sites in United States
- Volunteers
- 726 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily.
- Trial name
- NCT03341910
- Testing
- DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne…
- Trial name
- NCT02886715
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Where
- 25 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of…
- Trial name
- NCT06733402
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D